The company had posted a net profit of Rs 268.87 crore in the year-ago period, Alembic Pharmaceuticals said in a BSE filing.
Its consolidated total income from operations during the quarter under review also fell to Rs 777.03 crore from Rs 930.89 crore a year ago.
"The previous period includes revenues and profits from the Aripiprazole generic launch in the US market, which had limited competition. Hence the numbers are strictly not comparable," Alembic Pharmaceuticals said in a filing to BSE.
Shares of Alembic Pharmaceuticals were trading 0.56 per cent lower at Rs 582.15 ascrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content